We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Peregrine Completes Treatment of Last Patient in Phase II Cotara(R) Brain Cancer Trial
News

Peregrine Completes Treatment of Last Patient in Phase II Cotara(R) Brain Cancer Trial

Peregrine Completes Treatment of Last Patient in Phase II Cotara(R) Brain Cancer Trial
News

Peregrine Completes Treatment of Last Patient in Phase II Cotara(R) Brain Cancer Trial

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Peregrine Completes Treatment of Last Patient in Phase II Cotara(R) Brain Cancer Trial"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cotara is a targeted monoclonal antibody linked to a radioisotope that is administered as a single dose directly into the tumor, irradiating the tumor from the inside out, with minimal exposure to healthy tissue.

Interim median overall survival for patients treated with Cotara has ranged from 38 to 41 weeks, with 86 weeks from 14 patients at a single medical center. Expected survival is only approximately 24 weeks for recurrent GBM patients. Cotara has been granted orphan drug status and fast track designation for the treatment of GBM and anaplastic astrocytoma by the U.S. Food and Drug Administration.

"As currently approved therapies have failed to improve overall survival for recurrent GBM patients, the interim overall survival reported to date from our Cotara trials has been quite remarkable and we are eager to advance our treatment into a registrational trial," said Joseph S. Shan, vice president of clinical and regulatory affairs at Peregrine. "We expect top-line data to be available by mid-year 2011 and plan to meet with the FDA to define the optimal registration pathway for Cotara."

Advertisement